Zepzelca
Zepzelca ingredients
| Active ingredient | Strength |
|---|---|
| Lurbinectedin | .5 mg/mL |
What Zepzelca is used for
The FDA lists the approved uses on the official label (below). In the EU, lurbinectedin is approved as Zepzelca for:
Zepzelca, in combination with atezolizumab, is indicated for the maintenance treatment of adult patients with extensive-stage small cell lung cancer (ES-SCLC) whose disease has not progressed after first-line induction therapy with atezolizumab, carboplatin and etoposide.
EU wording from the European Medicines Agency; US approved uses can differ.
Key facts
- Brand
- Zepzelca
- Generic name
- Lurbinectedin
- Made by
- Jazz Pharmaceuticals, Inc.
- Forms
- Injection, Powder, Lyophilized, For Solution
- Given
- Intravenous
- Drug class
- Alkylating Drug
- FDA approval
- New drug application (NDA) NDA213702
- On the US market since
- 2020
Official information
- MedlinePlus drug information (search for Lurbinectedin)
Specialist medicine: started and supervised by a specialist doctor or hospital. This page is a plain-language summary of public official information, not medical advice; follow your doctor and the official product information.
Common questions
What is Zepzelca?
Zepzelca (Lurbinectedin) is a cancer medicine made by Jazz Pharmaceuticals, Inc., approved by the US FDA.
What are the ingredients of Zepzelca?
Zepzelca contains Lurbinectedin (.5 mg/mL).
Is Zepzelca approved in Europe?
The same active substance is approved in the EU as Zepzelca.
From the FDA National Drug Code directory (open.fda.gov, public domain) and the European Medicines Agency medicines list. Page made 5 November 2026 by Satya Babu.
← All specialty medicines, USA